Synthesis of 99mTc-HYNIC-interleukin-12, a new specific radiopharmaceutical for imaging T lymphocytes

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 4, 2006, Pages 474-482

  Annovazzi, Alessio ^a,e   D'Alessandria, Calogero ^a   Bonanno, Elena ^b   Mather, Stephen J ^c   Cornelissen, Bart ^d   Van De Wiele, Christophe ^d   Dierckx, Rudi A ^e   Mattei, Maurizio ^b   Palmieri, Graziana ^b   Scopinaro, Francesco ^a   Signore, Alberto ^a,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d GHENT UNIVERSITY   (Belgium)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

HYNIC; Interleukin 12; Molecular imaging; T lymphocytes

Indexed keywords

RADIOPHARMACEUTICAL AGENT; SUCCINIMIDYL 6 HYDRAZINOPYRIDINE 3 CARBOXYLATE INTERLEUKIN 12 TECHNETIUM TC 99M; UNCLASSIFIED DRUG; 99MTC HYNIC INTERLEUKIN 12; 99MTC-HYNIC-INTERLEUKIN-12; DIAGNOSTIC AGENT; INTERLEUKIN 12; TECHNETIUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL INFILTRATION; COLITIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG BINDING; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; EVALUATION; IMAGING SYSTEM; IN VITRO STUDY; INTESTINE; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; SPLEEN; T LYMPHOCYTE; THYMUS; ANIMAL; ANTIBODY SPECIFICITY; CELL LINE; CHEMISTRY; FEASIBILITY STUDY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; CELL LINE; COLITIS; FEASIBILITY STUDIES; INTERLEUKIN-12; ISOTOPE LABELING; MALE; METABOLIC CLEARANCE RATE; MICE; ORGAN SPECIFICITY; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 33645889985     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-0001-6     Document Type: Article

References (33)

1. Scott P. IL12: initiation cytokine for cell-mediated immunity. Science 1993;260:496-7
2. Stern AS, Magram J, Presky DH. Interleukin-12 an integral cytokine in the immune response. Life Sci 1996;58:639-54
3. Adorini L. Interleukin-12, a key cytokine in Th1-mediated autoimmune diseases. Cell Mol Life Sci 1999;55:1610-25
4. Desai BB, Quinn PM, Wolitzky AG, Mongini PK, Chizzonite R, Gately MK. IL12 receptor. II. Distribution and regulation of receptor expression. J Immunol 1992;148:3125-32
5. Chua AO, Chizzonite R, Desai BB, Truitt TP, Nunes P, Minetti LJ, et al. Expression cloning of a human IL12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol 1994;153:128-36
6. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998;8:275-83
7. Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol 2004;22:2891-900
8. Pockros PJ, Patel K, O'Brien C, Tong M, Smith C, Rustgi V, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 2003;37:1368-74
9. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med 1990;31:2022-8
10. King TP, Zhao SW, Lam T. Preparation of protein conjugates via intermolecular hydrazone linkage. Biochemistry 1986;25:5774-9
11. Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987;70:1069-72
12. 123I-interleukin-2: biochemical characterization and in vivo use for imaging autoimmune diseases. Nucl Med Commun 2003;24:305-16
13. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90
14. Signore A, Beales P, Sensi M, Zuccarini O, Pozzilli P. Labelling of lymphocytes with indium-111-oxine: effect on cell surface phenotype and antibody-dependent cellular cytotoxicity. Immunol Letters 1983;6:151-4
15. Jaakkola K, Knuuti J, Soderlund K, Saraste A, Jalkanen S, Voipio-Pulkki LM. Labelling lymphocytes with technetium99m-hexamethyl propyleneamine oxime for scintigraphy: an improved labelling procedure. J Immunol Methods 1998;214:187-97
16. Yamada Y, Uchida Y, Tatsumi K. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. J Nucl Med 1998;39:1160-6
17. Kara T, Kosaka N, Suzuki T. Uptake rates of F-18-fluorodeoxyglucose and C-11-choline in lung cancer and pulmonary tuberculosis - a positron emission tomography study. Chest 2003;124:893-901
18. 18F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study. J Nucl Med 2004;45:1245-50
19. Bartalena L, Tanda ML, Piantanida E, Lai A. The role of somatostatin analogs in the management of Graves' ophthalmopathy. J Endocrinol Invest 2003;26(8 Suppl):109-13
20. van Hagen PM, Breeman WA, Reubi JC, Postema PT, van den Anker-Lugtenburg PJ, Kwekkeboom DJ, et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996;23:1508-13
21. 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J Nucl Med 2001;42:154-61
22. Chianelli M, Parisella MG, D'Alessandria C, Corsetti F, Scopinaro F, Signore A. The developing role of peptide radiopharmaceuticals in the study of chronic inflammation: new techniques for novel therapeutic options. Q J Nucl Med 2003;47:256-69
23. Chianelli M, Signore A, Fritzberg AR, Mather SJ. The development of technetium-99m-labelled interleukin-2: a new radiopharmaceutical for the in vivo detection of mononuclear cell infiltrates in immune-mediated diseases. Nucl Med Biol 1997;24:579-86
24. 123I-labelled interleukin-2 scintigraphy for the in vivo assessment of intestinal mononuclear cell infiltration in Crohn's disease. J Nucl Med 2000;41:242-9
25. 123I-interleukin-2 and its response to diet. Eur J Nucl Med 2000;27:18-24
26. 99mTc-interleukin-2 scintigraphy as a potential tool for evaluating tumor-infiltrating lymphocytes in melanoma lesions: a validation study. J Nucl Med 2004;45:1647-52
27. Rennen HJ, Boerman OC, Koenders EB, Oyen WJ, Corstens FH. Labeling proteins with Tc-99m via hydrazinonicotinamide (HYNIC): optimization of the conjugation reaction. Nucl Med Biol 2000;27:599-604
28. 99mTc-labeled Hynic-derivatized annexin V for human use. Nucl Med Biol 2003;30:771-8
29. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, et al. Anti-IL-12 Crohn's Disease Study Group. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004;351:2069-79
30. Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol 2003;21:2564-73
31. Zou JJ, Schoenhaut DS, Carvajal DM, Warrier RR, Presky DH, Gately MK, et al. Structure-function analysis of the p35 subunit of mouse interleukin 12. J Biol Chem 1995;270:5864-71
32. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84
33. Kalden JR, Sieper J. Oral collagen in the treatment of rheumatoid arthritis. Arthritis Rheum 1998;41:191-4